Ariad Is Rolling Right On Track In Q3 With Its Lung Cancer Drug
Seeking Alpha,
I've written favorably on Ariad (NASDAQ: ARIA ) with respect to its developmental platforms and its expansion of current…
Ariad Is Worth A Look After Q2 Results
Seeking Alpha,
Ariad Pharmaceuticals (NASDAQ: ARIA ) has experienced some wild ups and downs over the past 5 years.
Identification of mutations causing lung cancer resistance leads to new treatment strategies
MedicalXpress,
Two mutations that cause lung cancer resistance to the investigational ALK inhibitor alectinib were identified, and this…
Identification of Novel Mutations Causing Lung Cancer Resistance Leads to New Treatment Strategies
Health Canal,
PHILADELPHIA — Two mutations that cause lung cancer resistance to the investigational ALK inhibitor alectinib were identified…